As part of our LiveTalk series, Being Patient spoke with Dr. Marwan Sabbagh, a neurologist and the director of the Cleveland Clinic Lou Ruvo…
While some scientists are focused on targeting beta-amyloid plaques to treat Alzheimer’s, others are honing in on another hallmark of the disease — pathological…
An Op-Ed by Benjamin Stecher Benjamin Stecher was diagnosed with Parkinson’s disease at the age of 29. He has since become actively involved in…
Alzheimer’s main hallmarks — beta-amyloid plaques and tau tangles — have long been the focus of the quest to come up with an Alzheimer’s…
The longstanding cholinergic hypothesis proposes that the cholinergic system — a network of neurons which passes information through a chemical messenger known as acetylcholine…
How can we differentiate between “normal” aging and mild cognitive impairment, the condition associated with early stages of neurodegenerative diseases like Alzheimer’s? Aging can…
The toxic accumulation of four abnormal proteins in the brain is such a harbinger of cognitive decline, one researcher has taken to calling them…